Shots:
Dr. Mourad spoke about the acceptance of aBLA for BIIB800, a Tocilizumab biosimilar candidate for several autoimmune diseases, including rheumatoid arthritis
He briefed about the study design and results from the P-III trial which supported the BLA filing
This interview focuses on Biogen's notable progress in addressing challenging immunologic conditions, offering potential solutions to…
Shots:
Gina gave her views on the acceptance of the sBLA by the US FDA and the validation of the Type II Variation Marketing Authorization Application by the EMA for Opdivo as monotherapy for the treatment of patients with completely resected stage IIB or IIC melanoma
She also spoke on the epidemiology of melanoma and…

